| |
| |
|
| Insider
Information: |
Deschatelets Pascal |
| Relationship: |
Chief Scientific Officer |
| City: |
Crestwood |
| State: |
KY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
1,115,983 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$48,991,654 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,115,983 |
|
|
| Total
Value |
$48,991,654 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -125.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Scientific Officer |
2024-04-08 |
1,115,983 |
2018-05-07 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-04-08 |
4 |
AS |
$54.12 |
$3,743,605 |
D/D |
(69,107) |
1,115,983 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-04-08 |
4 |
OE |
$3.76 |
$259,842 |
D/D |
69,107 |
1,185,090 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-03-08 |
4 |
AS |
$61.88 |
$4,297,549 |
D/D |
(69,107) |
1,115,983 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-03-08 |
4 |
OE |
$3.67 |
$253,623 |
D/D |
69,107 |
1,185,090 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-02-12 |
4 |
S |
$67.77 |
$77,796 |
D/D |
(1,148) |
1,115,983 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-01-29 |
4 |
S |
$64.14 |
$56,057 |
D/D |
(874) |
1,117,131 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-01-22 |
4 |
S |
$65.00 |
$254,329 |
D/D |
(3,913) |
1,118,005 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-01-16 |
4 |
S |
$66.81 |
$109,032 |
D/D |
(1,632) |
1,121,918 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
6,743 |
1,123,550 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-11-14 |
4 |
OE |
$3.76 |
$169,200 |
D/D |
45,000 |
1,116,807 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-11-08 |
4 |
AS |
$47.27 |
$567,240 |
D/D |
(12,000) |
1,071,807 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-11-08 |
4 |
OE |
$2.67 |
$46,709 |
D/D |
17,494 |
1,083,807 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-10-09 |
4 |
AS |
$40.38 |
$484,560 |
D/D |
(12,000) |
1,066,313 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-10-09 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,078,313 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-09-08 |
4 |
AS |
$42.87 |
$514,440 |
D/D |
(12,000) |
1,059,813 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-09-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,071,813 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-08-08 |
4 |
AS |
$23.66 |
$283,920 |
D/D |
(12,000) |
1,053,313 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-08-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,065,313 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-07-10 |
4 |
AS |
$84.55 |
$1,014,600 |
D/D |
(12,000) |
1,046,813 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-07-10 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,058,813 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-06-08 |
4 |
AS |
$91.35 |
$1,096,200 |
D/D |
(12,000) |
1,040,313 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-06-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,052,313 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-05-08 |
4 |
AS |
$92.39 |
$1,108,680 |
D/D |
(12,000) |
1,033,813 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-05-08 |
4 |
OE |
$2.67 |
$49,395 |
D/D |
18,500 |
1,045,813 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Scientific Officer |
• • – |
2023-04-10 |
4 |
AS |
$78.21 |
$938,520 |
D/D |
(12,000) |
1,027,313 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
